For patients with severe COVID-19, anti-IL-6 signaling agents displayed remarkable advantages in reducing mortality compared to SOC, consistent with the result above (pooled OR = 0.49, 95% CI 0.32–0.74, p = 0.0007). This evidence concerns the gene IL6 and COVID-19.